Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJM Brouwer… - Elife, 2021 - elifesciences.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
G Marloes, PJM Brouwer, B Mitch, M Pauline… - eLife, 2021 - search.proquest.com
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
M Grobben, K van der Straten, PJM Brouwer… - eLife, 2021 - go.gale.com
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
[PDF][PDF] Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
minerva-access.unimelb.edu.au
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJM Brouwer… - eLife, 2021 - cir.nii.ac.jp
抄録< jats: p> Current SARS-CoV-2 vaccines are losing efficacy against emerging variants
and may not protect against future novel coronavirus outbreaks, emphasizing the need for …
and may not protect against future novel coronavirus outbreaks, emphasizing the need for …
[引用][C] Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
M Grobben, K van der Straten, PJ Brouwer… - 2021 - rivm.openrepository.com
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Toggle navigation Login
Toggle navigation View Item Home Articles and other publications by RIVM employees …
Toggle navigation View Item Home Articles and other publications by RIVM employees …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJM Brouwer… - 2021 - agris.fao.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination.
M Grobben, K van der Straten, PJM Brouwer… - 2021 - cabidigitallibrary.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
[HTML][HTML] Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJ Brouwer… - 2021 - europepmc.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJM Brouwer… - medRxiv, 2021 - medrxiv.org
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …
protect against future novel coronavirus outbreaks, emphasizing the need for more broadly …